Lisa B E Shields1, Christopher B Shields2, Tom L Yao1, Brian M Plato1, Yi Ping Zhang1, Shervin R Dashti3. 1. Norton Neuroscience Institute, Norton Healthcare, Louisville, Kentucky, USA. 2. Norton Neuroscience Institute, Norton Healthcare, Louisville, Kentucky, USA; Department of Neurological Surgery, University of Louisville, Louisville, Kentucky, USA. 3. Norton Neuroscience Institute, Norton Healthcare, Louisville, Kentucky, USA. Electronic address: Shervin.Dashti@nortonhealthcare.org.
Abstract
BACKGROUND: Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure. IIH causes significant morbidity marked by incapacitating headaches and visual disturbances. This study investigated the long-term outcomes of venous sinus stenting in a large group of patients with IIH. METHODS: We retrospectively reviewed all patients at our institution who underwent venous sinus stenting for IIH over 6 years (July 1, 2012-June 30, 2018). A particular focus was dedicated to collecting demographic, clinical, radiologic, and outcomes data. All patients had failed medical management. RESULTS: Of the 110 patients evaluated for IIH, 42 underwent venous sinus stenting, with a mean follow-up of 25.6 months (range, 8.7-60.7 months). The mean age was 32 years (range, 15-52 years), 38 (90%) were women, and the mean body mass index was 35.6 kg/m2 (range, 18.6-47.5 kg/m2). Prior to the stenting procedure, all patients had headaches, visual disturbances, and papilledema. Of the 39 patients who had an ophthalmologic evaluation poststenting, 29 (74%) had resolution of their papilledema. Eighteen patients (43%) had complete resolution of their headaches after the stenting procedure, whereas 22 patients (52%) remained under a neurologist's care for chronic migraine and other types of headaches. Two patients underwent a restenting procedure for disease progression, and 1 patient experienced an in-stent thrombosis. CONCLUSIONS: A multidisciplinary approach involving neurosurgeons, ophthalmologists, radiologists, and neurologists is integral in the management of patients with IIH to prevent the complications of papilledema. Venous sinus stenting offers a safe and effective means of treating IIH.
BACKGROUND:Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure. IIH causes significant morbidity marked by incapacitating headaches and visual disturbances. This study investigated the long-term outcomes of venous sinus stenting in a large group of patients with IIH. METHODS: We retrospectively reviewed all patients at our institution who underwent venous sinus stenting for IIH over 6 years (July 1, 2012-June 30, 2018). A particular focus was dedicated to collecting demographic, clinical, radiologic, and outcomes data. All patients had failed medical management. RESULTS: Of the 110 patients evaluated for IIH, 42 underwent venous sinus stenting, with a mean follow-up of 25.6 months (range, 8.7-60.7 months). The mean age was 32 years (range, 15-52 years), 38 (90%) were women, and the mean body mass index was 35.6 kg/m2 (range, 18.6-47.5 kg/m2). Prior to the stenting procedure, all patients had headaches, visual disturbances, and papilledema. Of the 39 patients who had an ophthalmologic evaluation poststenting, 29 (74%) had resolution of their papilledema. Eighteen patients (43%) had complete resolution of their headaches after the stenting procedure, whereas 22 patients (52%) remained under a neurologist's care for chronic migraine and other types of headaches. Two patients underwent a restenting procedure for disease progression, and 1 patient experienced an in-stent thrombosis. CONCLUSIONS: A multidisciplinary approach involving neurosurgeons, ophthalmologists, radiologists, and neurologists is integral in the management of patients with IIH to prevent the complications of papilledema. Venous sinus stenting offers a safe and effective means of treating IIH.
Authors: Robert Kyle Townsend; Alec Jost; Matthew R Amans; Ferdinand Hui; Matthew T Bender; Sudhakar R Satti; Robert Maurer; Kenneth Liu; Waleed Brinjikji; Kyle M Fargen Journal: J Neurointerv Surg Date: 2021-04-28 Impact factor: 5.836
Authors: Mark J Rosenberg; Michael A Coker; James A Taylor; Milad Yazdani; M Gisele Matheus; Christopher K Blouin; Sami Al Kasab; Heather R Collins; Donna R Roberts Journal: JAMA Netw Open Date: 2021-10-01
Authors: Aqib H Zehri; Katriel E Lee; Jeff Kartchner; Madison Arnel; Timothy Martin; Stacey Q Wolfe; Kyle M Fargen Journal: Neuroradiol J Date: 2021-07-05
Authors: Nebiyat F Belachew; Severin Baschung; William Almiri; Ruben Encinas; Johannes Kaesmacher; Tomas Dobrocky; Christoph J Schankin; Mathias Abegg; Eike I Piechowiak; Andreas Raabe; Jan Gralla; Pasquale Mordasini Journal: Clin Neuroradiol Date: 2021-05-18 Impact factor: 3.649